Skip Nav Destination
Chapter 1, Consultative hematology 1: perioperative management concepts
Jordan Schaefer: research funding from the National Institutes of Health, American Society of Hematology, and Hemostasis and Thrombosis Research Society; consultancy: Pfizer, Sanofi outside the current work.
Geoffery Barnes: grant funding from Boston Scientific; consulting fees from Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, Boston Scientific; board of directors for Anticoagulation Forum.
Chapter 2, Consultative hematology 2: outpatient hematology topics
Jennifer R. Green: research funding: Health Resources and Services Administration; honoraria: American Society of Hematology, Sobi; membership on advisory board: Sobi.
Chapter 3, Consultative hematology 3: women’s health issues
Imo J. Akpan: advisory board, speakers bureau, consulting, honoraria: Pharmacosmos.
Chapter 4, Pediatric hematology: selected topics
Shelley E. Crary: advisory board membership: Pfizer, Medexus, Sanofi, CSL Behring; consultancy for data safety monitoring board: ASC Therapeutics, Novartis.
Chapter 5, Hematopoietic growth factors
Elizabeth A. Griffiths: Advisory board/honorarium payments from AbbVie, Alexion Pharmaceuticals, Apellis, Cel-Digene/ BMS, CTI Biopharma, Genentech, Novartis, Picnic Health, Servier, Takeda Oncology, and Taiho Oncology; research funding to Roswell Park Cancer Institute: Astex Pharmaceuticals, AstraZeneca Rare Disease, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Blueprint Medicines, Genentech Inc, and NextCure.
Chapter 6, Iron physiology, iron overload, and the porphyrias
Jason Freed: nothing to disclose.
Rebecca Karp Leaf: consultancy: Alnylam Pharmaceutics, Recordati Rare Diseases.
Chapter 7, Acquired underproduction anemias: anemias in the setting of vitamin and mineral deficiencies
Jacquelyn Powers: nothing to disclose.
Chapter 8, Anemia of inflammation
Brady L. Stein: nothing to disclose.
Chapter 9, Anemia in the setting of organ insult, systemic disease, and aging
Maria Domenica Cappellini: consultancy: Bristol-Myers Squibb, Sanofi/Genzyme, Novo Nordisk, Agios, Silence, Pharmacosmos, Vertex, Pfizer.
Chapter 10, Thalassemia syndromes and other hemoglobinopathies
Sujit Sheth: Grants or contracts: Research funding, contract with institution: BMS/Celgene, Forma, Agios; Consulting, advisory board member: Agios, Bluebird Bio, Fulcrum, Regeneron, Chiesi, BMS/Celgene; Consulting, steering committee member; Vertex; Honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events, participation in continuing medical education (CME) activities: Plexus, CCO, PER. Support for and/or travel to advisory board meetings: Agios, BMS/Celgene, Bluebird Bio. Participation on a data safety monitoring board or advisory board: CRISPR/Vertex (clinical trial steering committee).
Chapter 11, Sickle cell disease
Lydia H. Pecker: Grants or contracts: research funding: The US Food and Drug Administration’s Office of Women’s Health/Johns Hopkins Center for Excellence in Regulatory Science, The Andrew W. Mellon Foundation, Affimmune, and Novartis; consulting, advisory board member: Pfizer and Novo Nordisk; honoraria for lectures, presentations, or educational events: Pfizer.
Chapter 12, Hemolytic anemia 1: autoimmune hemolysis
Samuel A. Merrill: member of scientific advisory board: Alexion, Genentech; consultancy: Sanofi-Genzyme.
Chapter 13, Hemolytic anemia 2: membrane abnormalities and enzymopathies
Rachael F. Grace: research funding: Novartis, Agios, Sobi; consultancy: Agios, Sanofi, Sobi
Chapter 14, Complement-related disorders
Jamile M. Shammo: consultancy: Alexion/AstraZeneca, Apellis Pharmaceuticals, Bristol-Myers Squibb, Sobi, Celgene, GSK, MJH, Novartis, Sanofi, Omeros, Regeneron, Curio Science; research funding: Alexion, AstraZeneca, Apellis, Incyte, Novartis, Protagonist Therapeutics; speakers’ bureau: Alexion, Bristol-Myers Squibb, Sobi, Sanofi; membership on a board or advisory committee: Apellis Pharmaceuticals, GSK, MJH. Equity ownership: AbbVie, Baxter.
Chapter 15, Introduction to venous thromboembolism and antithrombotic drugs
Joseph J. Shatzel: nothing to disclose.
Marcin Wlodarski: nothing to disclose
Chapter 16, Atypical-site thrombosis
Carol Mathew: consultancy: Magellan Rx.
Chapter 17, Antiphospholipid syndrome
Karlyn Martin: consultancy: Endovascular Engineering, Penumbra.
Chapter 18, Cancer-associated thrombosis
Ang Li: nothing to disclose.
Chapter 19, Inherited thrombophilias
Bethany T. Samuelson Bannow: advisory board: Hema Biologics.
Chapter 20, von Willebrand disease
Clay T. Cohen: Advisory board: Bayer Pharmaceuticals, CSL Behring, Sanofi, Octapharma.
Chapter 21, Hemophilia A and B
Sven Olson: nothing to disclose.
Chapter 22, Hereditary hemorrhagic telangiectasia and other bleeding disorders
Raj S. Kasthuri is a member of the Guidelines Working Group for the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Consultancy: Alnylam, Crosswalk Therapeutics, and Pharmacosmos. Hanny Al-Samkari is a member of the Guidelines Working Group for the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Consultancy: Agios, Amgen, Alpine, Alnylam, Argenx, Sobi, Pharmacosmos, Sanofi, and Novartis and received research funding to the institution from Agios, Amgen, Novartis, Sobi, and Vaderis.
Chapter 23, Platelet disorders 1: immune thrombocytopenia
Taylor Olmsted Kim: nothing to disclose.
Chapter 24, Platelet disorders 2: heparin-induced thrombocytopenia and other anti-PF4 disorders
Andreas Greinacherreports grants and nonfinancial support from Aspen, Boehringer Ingelheim, MSD, Bristol-Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc., Rovi, Sagent, and Biomarin/Prosensa; personal fees from Aspen, Boehringer Ingelheim, MSD, Macopharma, BMS, Chromatec, and Werfen (Instrumentation Laboratory); and nonfinancial support from Boehringer Ingelheim, Portola, Ergomed, GTH e.V., and Universitätsmedizin. Greifswald is one of the owners of a patent for a solid phase assay to detect HIT and VITT antibodies.
Chapter 25, Platelet disorders 3: thrombotic thrombocytopenic purpura (immune and congenital) Senthil Sukumar: consultancy: Sanofi-Genzyme.
Chapter 26, Platelet disorders 4: hereditary thrombocytopenia and qualitative platelet disorders Hanny Al-Samkari:Consultancy: Agios, Amgen, Alpine, Alnylam, Argenx, Sobi, Pharmacosmos, Sanofi, and Novartis and received research funding to the institution from Agios, Amgen, Novartis, Sobi, and Vaderis.
Chapter 27, Laboratory hematology Kenneth D. Friedman:consultancy: Genentech, Sanofi, Siemens, Takeda, Werfen; honoraria for speaking: Siemens, Werfen; advisory board: Werfen.
Jason H. Kurzer: nothing to disclose.
Chapter 28, Transfusion medicine Michelle P. Zeller: Financial payments and honoraria: Pfizer: speaking honoraria and travel expenses for an educational conference; ORBCoN, TTISS, and PriMed: speaking honoraria; Iron Consortium Conference: participation honoraria; Octapharma: clinical trial audit expenses. Advisory boards or speakers’ bureaus: Pfizer: advisory board membership and scientific meeting. Research grants or consulting fees: Canadian Blood Services: consultancy; CIHR, CBS, and Pfizer Global Medical Grant: research funding; McMaster University: Mid-Career Award.
Grace M. Lee: Research funding: AABB and Adamas Nanotechnologies.
Chapter 29, Apheresis Jay S. Raval is a consultant, advisor, and speaker for Sanofi SA. He is also a member of the board of directors of the American Society for Apheresis.
Chapter 30, Hematopoietic cell transplantation and cellular therapy 1: the basics of transplantation Christopher R. D’Angelo: consultancy: Bristol-Myers Squibb, Seagen, AbbVie; research funding: BeiGene, Bristol-Myers Squibb, Ono Pharma, Curis Inc, Fate Therapeutics.
Chapter 31, Hematopoietic cell transplantation and cellular therapy 2: autologous transplantation Benjamin A. Derman: Consultancy: Janssen, Sanofi, Canopy, and Cota Inc. Independent review committee: Bristol-Myers Squibb. Research funding: GSK, Amgen.
Chapter 32, Hematopoietic cell transplantation and cellular therapy 3: allogeneic transplantation and graft-versus- host disease Shernan Holtan receives research funding from Vitrac Therapeutics and Incyte, adjudicates clinical trial data for CSL Behring, provides educational content for Sanofi/Kadmon, and has performed consulting services for Ossium and MaaT Pharma.
Chapter 33, Hematopoietic cell transplantation and cellular therapy 4: adoptive cellular therapy Melody Smith reports consulting for CVS Caremark and is an advisor for A28 Therapeutics outside the submitted work. In addition, Dr. Smith has a patent (US 17/229,184) issued, and patents (US 63/303,461 and Stanford Docket S23–380) pending.
Chapter 34, Myeloid disorders: acquired and inherited white blood cell disorders Bhumika J. Patel: nothing to disclose.
Chapter 35, Inherited bone marrow failure syndromes Michael W. Drazer: Consultancy; Argenx, Blueprint Medicines.
Chapter 36, Chronic myeloid leukemia Maximillian Stahl:advisory board membership; Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi and Syndax; consulted; Boston Consulting, Dedham Group, and Kura Oncology; participated in GME activity; Novartis, Curis Oncology, Haymarket Media, Clinical Care Options.
Chapter 37, Myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis Brady Stein: nothing to disclose.
Anand A. Patel: honoraria from AbbVie, Bristol-Myers Squibb, Sobi; research funding (institutional) from Pfizer, Kronos Bio, Sumitomo.
Chapter 38, Beyond the classical Philadelphia chromosome–negative myeloproliferative neoplasms Anand A. Patel: research funding (to institution): Pfizer, Kronos Bio, Sumitomo; honoraria: AbbVie, Bristol-Myers Squibb, Sobi.
Brady Stein: nothing to disclose.
Chapter 39, Acquired bone marrow failure syndromes, including aplastic anemia and pure red cell aplasia Emma M. Groarke: nothing to disclose.
Chapter 40, Myelodysplastic syndromes and premalignant clonal hematopoiesis Lachelle D. Weeks: consultancy: AbbVie, Sobi, and Vertex.
Chapter 41, Acute myeloid leukemia Catherine C. Smith has received research funding from Revolution Medicines, Erasca, and AbbVie and has served on advisory boards for AbbVie, Genentech, and Servier.
Chapter 42, Acute lymphoblastic leukemia Lori Muffly: consultancy: Astellas; research funding: Astellas, Adaptive, BMS, Jasper, Kite, Vor, Wugen; advisory boards: Autolus, Cargo, Kite, Pfizer.
Chapter 43, Hodgkin lymphoma Matthew Mei: Consultancy: Novartis, SeaGen, ADC, Astra- Zeneca, and Synethkine. Speakers’ bureau: SeaGen, Incyte. Research funding: BMS, BeiGene, Incyte, Genentech.
Chapter 44, Indolent non-Hodgkin B-cell lymphoma Sairah Ahmed: Research support to institution for clinical trials from Nektar, Merck, Xencor, Chimagen, and Genmab, Kite/Gilead, Janssen, and Caribou. Consultant for ADC Therapeutics, Kite/Gilead, Genmab, and BMS.
Chapter 45, Aggressive non-Hodgkin and Burkitt lymphomas Allison Rosenthal has received honoraria for educational sessions from Curio Science, RMEI Medical Education LLC, OncLive, and Targeted Oncology.
Chapter 46, T-cell lymphomas Neha Mehta-Shah has received institutional clinical trial funding from AstraZeneca, Bristol-Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Secura Bio/ Verastem, Yingli Pharmaceuticals, Morphosys/Novartis, SeaGen, and Dizal Pharmaceuticals. She has received compensation for service as a consultant for AstraZeneca, Secura Bio/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Janssen Karyopharm Therapeutics, Kyowa Hakko Kirin, Ono Pharmaceuticals, Pfizer, and Autolus.
Chapter 47, Chronic lymphocytic leukemia/small lymphocytic lymphoma Jennifer A. Woyach: consulted for AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo/Lilly, Merck, Newave, and Pharmacyclics and receives research funding from AbbVie, Janssen, Pharmacyclics, and Schrödinger.
Chapter 48, Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma Caitlin L.Costello: honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, Kite, and Pfizer; Research funding from Bristol-Myers Squibb, Janssen, Pfizer, Poseida and Takeda.
Chapter 49, AL amyloidosis, Waldenström macroglobulinemia, and POEMS syndrome Vaishali Sanchorawala: Advisory board and consultancy for GlaxoSmithKline; research funding (to the institution) from Janssen, Alexion, and Prothena; steering committee for Janssen; advisory board meetings for Prothena, AbbVie, Regeneron, Janssen, and Alexion.
Chapter 1, Consultative hematology 1: perioperative management concepts
Fondaparinux for heparin-induced thrombocytopenia; prothrombin complex concentrates for bleeding associated with direct oral anticoagulants.
Chapter 2, Consultative hematology 2: outpatient hematology topics
Granulocyte-stimulating factor outside of severe congenital neutropenia.
Chapter 3, Consultative hematology 3: women’s health issues
Almost all medications are considered off-label in pregnancy
Chapter 4, Pediatric hematology: selected topics
Rituximab for ITP.
Chapter 5, Hematopoietic growth factors
TPO mimetics (romipolostim, eltrombopag, avatrombopag) for chemotherapy-induced thrombocytopenia and myelodysplastic syndrome and to improve posttransplant stem cell recovery or cellular therapy.
Chapter 6, Iron physiology, iron overload, and the porphyrias
Iron chelation therapy.
Chapter 7, Acquired underproduction anemias: anemias in the setting of vitamin and mineral deficiencies
IV iron therapy for pediatric patients with iron deficiency anemia is discussed.
Chapter 8, Anemia of inflammation
Not applicable.
Chapter 9, Anemia in the setting of organ insult, systemic disease, and aging
Not applicable.
Chapter 10, Thalassemia syndromes and other hemoglobinopathies Not applicable.
Chapter 11, Sickle cell disease
Not applicable.
Chapter 12, Hemolytic anemia 1: autoimmune hemolysis
Alemtuzumab, azathioprine, bortezomib, cyclophosphamide, cyclosporine, daratumumab, danazol, erythropoietin, fostimatinib, intravenous immunoglobulin (IVIG), mycophenolate mofetil, and rituximab in the treatment of warm autoimmune hemolytic anemia. Bendamustine, ibrutinib, and rituximab in the treatment of cold agglutinin disease.
Chapter 13, Hemolytic anemia 2: membrane abnormalities and enzymopathies
Not applicable.
Chapter 14, Complement-related disorders
Not applicable.
Chapter 15, Introduction to venous thromboembolism and antithrombotic drugs
4-factor PCC for the reversal of DOAC associated bleeding.
Chapter 16, Atypical-site thrombosis
Direct oral anticoagulants (DOACs) for atypical-site thrombosis, intravenous immunoglobulins (IVIG) for VITT.
Chapter 17, Antiphospholipid syndrome
Not applicable.
Chapter 18, Cancer-associated thrombosis
The use of prophylactic anticoagulant in the ambulatory setting is off-label.
Chapter 19, Inherited thrombophilias
Not applicable.
Chapter 20, von Willebrand disease
Not applicable.
Chapter 21, Hemophilia A and B
Serpin-PC for hemophilia A and B; rituximab for inhibitor eradication in congenital hemophilia A; cyclophosphamide and rituximab for acquired hemophilia A.
Chapter 22, Hereditary hemorrhagic telangiectasia and other bleeding disorders
Tranexamic acid, epsilon-aminocaproic acid, bevacizumab, thalidomide, pomalidomide, pazopanib, and tacrolimus for HHT; tranexamic acid and epsilon-aminocaproic acid for disorders of fibrinolysis.
Chapter 23, Platelet disorders 1: immune thrombocytopenia
Eltrombopag and romiplostim in newly diagnosed ITP; rituximab, mycophenolate mofetil, azathioprine, 6-mercaptopurine, sirolimus, cyclosporine, vinca alkaloids, dapsone, and danazol in treatment of ITP.
Chapter 24, Platelet disorders 2: heparin-induced thrombocytopenia and other anti-PF4 disorders
None of the alternative anticoagulants, except argatroban, is approved for HIT. Bivalirudin is approved for HIT only in patients undergoing cardiac surgery in case of HIT or increased risk for HIT. For VITT and VITT-like disorders, no anticoagulant is approved. IVIG is not approved for HIT, VITT, or VITT-like disorders.
Chapter 25, Platelet disorders 3: thrombotic thrombocytopenic purpura (immune and congenital)
Rituximab as immunosuppressive therapy for thrombotic thrombocytopenic purpura.
Chapter 26, Platelet disorders 4: hereditary thrombocytopenia and qualitative platelet disorders
Antifibrinolytic agents (tranexamic acid and epsilon-aminocaproic acid) for inherited platelet function disorders. Desmopressin for uremic platelet dysfunction and inherited platelet function disorders. Thrombopoietin receptor agonists for hereditary thrombocytopenias. Recombinant factor VIIa for non-Glanzmann thrombasthenia inherited platelet function disorders.
Chapter 27, Laboratory hematology
Not applicable.
Chapter 28, Transfusion medicine
Not applicable.
Chapter 29, Apheresis
Not applicable.
Chapter 30, Hematopoietic cell transplantation and cellular therapy 1: the basics of transplantation
Not applicable.
Chapter 31, Hematopoietic cell transplantation and cellular therapy 2: autologous transplantation
Not applicable.
Chapter 32, Hematopoietic cell transplantation and cellular therapy 3: allogeneic transplantation and graft-versus- host disease
All drugs discussed in this chapter are considered off-label with the exception of abatacept, belumosudil, ibrutinib, and ruxolitinib.
Chapter 33, Hematopoietic cell transplantation and cellular therapy 4: adoptive cellular therapy
Not applicable.
Chapter 34, Myeloid disorders: acquired and inherited white blood cell disorders
Granulocyte colony-stimulating factor (G-CSF) in non-SCN neutropenia; glucocorticoids in autoimmune neutropenias, and histiocytic syndromes; interferon-γ in Erdheim-Chester disease; plerixafor in WHIM syndrome; intravenous immunoglobin in autoimmune neutropenias; interferon-γ in chronic granulomatous disease; colchicine in familial Mediterranean fever; etoposide, methotrexate, cyclosporine, anti-thymocyte globulin, and dexamethasone in hemophagocytic lymphohistiocytosis; topical steroids, nitrogen mustard, psoralen in Langerhans cell histiocytosis; vinblastine, methotrexate, and glucocorticoids in Langerhans cell histiocytosis.
Chapter 35, Inherited bone marrow failure syndromes
Not applicable.
Chapter 36, Chronic myeloid leukemia
Not applicable.
Chapter 37, Myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis
Interferon for MPNs.
Chapter 38, Beyond the classical Philadelphia chromosome–negative myeloproliferative neoplasms
Ruxolitinib for CNL and aCML.
Chapter 39, Acquired bone marrow failure syndromes, including aplastic anemia and pure red cell aplasia
Cyclophosphamide, CSA, azathioprine, sirolimus, ATG, alemtuzumab, and rituximab in PRCA. Romiplostim and alemtuzumab in SAA.
Chapter 40, Myelodysplastic syndromes and premalignant clonal hematopoiesis
Epoetin and darbepoetin alfa; filgrastim and tbo-filgrastim; eltrombopag and romiplostim; ventoclax; ivosidenib; enosidenib.
Chapter 41, Acute myeloid leukemia
Gilteritinib (posttransplant maintenance).
Chapter 42, Acute lymphoblastic leukemia
Blinatumomab, inotuzumab.
Chapter 43, Hodgkin lymphoma
Lenalidomide, temsirolimus, and everolimus for cHL.
Chapter 44, Indolent non-Hodgkin B-cell lymphoma
Not applicable.
Chapter 45, Aggressive non-Hodgkin and Burkitt lymphomas
Venetoclax in R/R MCL, Liso-Cel in CNSL, lenalidomide, pomalidomide, ibrutinib, PD-1 inhibitors in R/R CNSL, brentuximab and nivolumab in PMBCL, brentuximab vedotin, lenalidomide and Bruton’s tyrosine kinase inhibitors in R/R DBLCL, CAR-T in CNSL.
Chapter 46, T-cell lymphomas
Duvelisib, valemetostat, golidicitinib, azacitidine for PTCL, mogamulizumab, valemetostat, lenalidomide in adult T-cell leukemia/lymphoma.
Chapter 47, Chronic lymphocytic leukemia/small lymphocytic lymphoma
Not applicable.
Chapter 48, Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma
Venetoclax is not approved for the treatment of multiple myeloma. Proteasome inhibitors and anti-CD38 monoclonal antibodies are not approved for maintenance therapies for multiple myeloma.
Chapter 49, AL amyloidosis, Waldenström macroglobulinemia, and POEMS syndrome
Melphalan, lenalidomide, pomalidomide, bortezomib, cyclophosphamide, dexamethasone, ixazomib, belantamab mafodotin, CAR-T, bispecific antibodies for the treatment of AL amyloidosis.
Disclosures
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), the American Society of Hematology must ensure balance, independence, objectivity, and scientific rigor in all of the educational activities it sponsors. All individuals in control of content are expected to disclose any financial relationships with ineligible companies that have occurred within the previous 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. If an individual has such an interest, then they must disclose the name of the ineligible company and nature of the relationship (eg, consultant or grantee). An individual who has no such financial relationship with an ineligible company must declare that they have nothing to disclose. The intent of this disclosure is not to prevent an individual with a significant financial or other relationship from making a presentation, but rather to provide readers with information that they can use to make their own judgments. It remains for the audience to determine whether the individual’s interests or relationships may influence the work with regard to exposition or conclusion.
Review disclosure of editor and reviewer financial relationships
Disclosures of author financial relationships
All relevant financial relationships have been mitigated. Staff planners have nothing to disclose.
Chapter 1, Consultative hematology 1: perioperative management concepts
Jordan Schaefer: research funding from the National Institutes of Health, American Society of Hematology, and Hemostasis and Thrombosis Research Society; consultancy: Pfizer, Sanofi outside the current work.
Geoffery Barnes: grant funding from Boston Scientific; consulting fees from Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, Boston Scientific; board of directors for Anticoagulation Forum.
Chapter 2, Consultative hematology 2: outpatient hematology topics
Jennifer R. Green: research funding: Health Resources and Services Administration; honoraria: American Society of Hematology, Sobi; membership on advisory board: Sobi.
Chapter 3, Consultative hematology 3: women’s health issues
Imo J. Akpan: advisory board, speakers bureau, consulting, honoraria: Pharmacosmos.
Chapter 4, Pediatric hematology: selected topics
Shelley E. Crary: advisory board membership: Pfizer, Medexus, Sanofi, CSL Behring; consultancy for data safety monitoring board: ASC Therapeutics, Novartis.
Chapter 5, Hematopoietic growth factors
Elizabeth A. Griffiths: Advisory board/honorarium payments from AbbVie, Alexion Pharmaceuticals, Apellis, Cel-Digene/ BMS, CTI Biopharma, Genentech, Novartis, Picnic Health, Servier, Takeda Oncology, and Taiho Oncology; research funding to Roswell Park Cancer Institute: Astex Pharmaceuticals, AstraZeneca Rare Disease, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Blueprint Medicines, Genentech Inc, and NextCure.
Chapter 6, Iron physiology, iron overload, and the porphyrias
Jason Freed: nothing to disclose.
Rebecca Karp Leaf: consultancy: Alnylam Pharmaceutics, Recordati Rare Diseases.
Chapter 7, Acquired underproduction anemias: anemias in the setting of vitamin and mineral deficiencies
Jacquelyn Powers: nothing to disclose.
Chapter 8, Anemia of inflammation
Brady L. Stein: nothing to disclose.
Chapter 9, Anemia in the setting of organ insult, systemic disease, and aging
Maria Domenica Cappellini: consultancy: Bristol-Myers Squibb, Sanofi/Genzyme, Novo Nordisk, Agios, Silence, Pharmacosmos, Vertex, Pfizer.
Chapter 10, Thalassemia syndromes and other hemoglobinopathies
Sujit Sheth: Grants or contracts: Research funding, contract with institution: BMS/Celgene, Forma, Agios; Consulting, advisory board member: Agios, Bluebird Bio, Fulcrum, Regeneron, Chiesi, BMS/Celgene; Consulting, steering committee member; Vertex; Honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events, participation in continuing medical education (CME) activities: Plexus, CCO, PER. Support for and/or travel to advisory board meetings: Agios, BMS/Celgene, Bluebird Bio. Participation on a data safety monitoring board or advisory board: CRISPR/Vertex (clinical trial steering committee).
Chapter 11, Sickle cell disease
Lydia H. Pecker: Grants or contracts: research funding: The US Food and Drug Administration’s Office of Women’s Health/Johns Hopkins Center for Excellence in Regulatory Science, The Andrew W. Mellon Foundation, Affimmune, and Novartis; consulting, advisory board member: Pfizer and Novo Nordisk; honoraria for lectures, presentations, or educational events: Pfizer.
Chapter 12, Hemolytic anemia 1: autoimmune hemolysis
Samuel A. Merrill: member of scientific advisory board: Alexion, Genentech; consultancy: Sanofi-Genzyme.
Chapter 13, Hemolytic anemia 2: membrane abnormalities and enzymopathies
Rachael F. Grace: research funding: Novartis, Agios, Sobi; consultancy: Agios, Sanofi, Sobi
Chapter 14, Complement-related disorders
Jamile M. Shammo: consultancy: Alexion/AstraZeneca, Apellis Pharmaceuticals, Bristol-Myers Squibb, Sobi, Celgene, GSK, MJH, Novartis, Sanofi, Omeros, Regeneron, Curio Science; research funding: Alexion, AstraZeneca, Apellis, Incyte, Novartis, Protagonist Therapeutics; speakers’ bureau: Alexion, Bristol-Myers Squibb, Sobi, Sanofi; membership on a board or advisory committee: Apellis Pharmaceuticals, GSK, MJH. Equity ownership: AbbVie, Baxter.
Chapter 15, Introduction to venous thromboembolism and antithrombotic drugs
Joseph J. Shatzel: nothing to disclose.
Marcin Wlodarski: nothing to disclose
Chapter 16, Atypical-site thrombosis
Carol Mathew: consultancy: Magellan Rx.
Chapter 17, Antiphospholipid syndrome
Karlyn Martin: consultancy: Endovascular Engineering, Penumbra.
Chapter 18, Cancer-associated thrombosis
Ang Li: nothing to disclose.
Chapter 19, Inherited thrombophilias
Bethany T. Samuelson Bannow: advisory board: Hema Biologics.
Chapter 20, von Willebrand disease
Clay T. Cohen: Advisory board: Bayer Pharmaceuticals, CSL Behring, Sanofi, Octapharma.
Chapter 21, Hemophilia A and B
Sven Olson: nothing to disclose.
Chapter 22, Hereditary hemorrhagic telangiectasia and other bleeding disorders
Raj S. Kasthuri is a member of the Guidelines Working Group for the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Consultancy: Alnylam, Crosswalk Therapeutics, and Pharmacosmos. Hanny Al-Samkari is a member of the Guidelines Working Group for the Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Consultancy: Agios, Amgen, Alpine, Alnylam, Argenx, Sobi, Pharmacosmos, Sanofi, and Novartis and received research funding to the institution from Agios, Amgen, Novartis, Sobi, and Vaderis.
Chapter 23, Platelet disorders 1: immune thrombocytopenia
Taylor Olmsted Kim: nothing to disclose.
Chapter 24, Platelet disorders 2: heparin-induced thrombocytopenia and other anti-PF4 disorders
Andreas Greinacherreports grants and nonfinancial support from Aspen, Boehringer Ingelheim, MSD, Bristol-Myers Squibb (BMS), Paringenix, Bayer Healthcare, Gore Inc., Rovi, Sagent, and Biomarin/Prosensa; personal fees from Aspen, Boehringer Ingelheim, MSD, Macopharma, BMS, Chromatec, and Werfen (Instrumentation Laboratory); and nonfinancial support from Boehringer Ingelheim, Portola, Ergomed, GTH e.V., and Universitätsmedizin. Greifswald is one of the owners of a patent for a solid phase assay to detect HIT and VITT antibodies.
Chapter 25, Platelet disorders 3: thrombotic thrombocytopenic purpura (immune and congenital) Senthil Sukumar: consultancy: Sanofi-Genzyme.
Chapter 26, Platelet disorders 4: hereditary thrombocytopenia and qualitative platelet disorders Hanny Al-Samkari:Consultancy: Agios, Amgen, Alpine, Alnylam, Argenx, Sobi, Pharmacosmos, Sanofi, and Novartis and received research funding to the institution from Agios, Amgen, Novartis, Sobi, and Vaderis.
Chapter 27, Laboratory hematology Kenneth D. Friedman:consultancy: Genentech, Sanofi, Siemens, Takeda, Werfen; honoraria for speaking: Siemens, Werfen; advisory board: Werfen.
Jason H. Kurzer: nothing to disclose.
Chapter 28, Transfusion medicine Michelle P. Zeller: Financial payments and honoraria: Pfizer: speaking honoraria and travel expenses for an educational conference; ORBCoN, TTISS, and PriMed: speaking honoraria; Iron Consortium Conference: participation honoraria; Octapharma: clinical trial audit expenses. Advisory boards or speakers’ bureaus: Pfizer: advisory board membership and scientific meeting. Research grants or consulting fees: Canadian Blood Services: consultancy; CIHR, CBS, and Pfizer Global Medical Grant: research funding; McMaster University: Mid-Career Award.
Grace M. Lee: Research funding: AABB and Adamas Nanotechnologies.
Chapter 29, Apheresis Jay S. Raval is a consultant, advisor, and speaker for Sanofi SA. He is also a member of the board of directors of the American Society for Apheresis.
Chapter 30, Hematopoietic cell transplantation and cellular therapy 1: the basics of transplantation Christopher R. D’Angelo: consultancy: Bristol-Myers Squibb, Seagen, AbbVie; research funding: BeiGene, Bristol-Myers Squibb, Ono Pharma, Curis Inc, Fate Therapeutics.
Chapter 31, Hematopoietic cell transplantation and cellular therapy 2: autologous transplantation Benjamin A. Derman: Consultancy: Janssen, Sanofi, Canopy, and Cota Inc. Independent review committee: Bristol-Myers Squibb. Research funding: GSK, Amgen.
Chapter 32, Hematopoietic cell transplantation and cellular therapy 3: allogeneic transplantation and graft-versus- host disease Shernan Holtan receives research funding from Vitrac Therapeutics and Incyte, adjudicates clinical trial data for CSL Behring, provides educational content for Sanofi/Kadmon, and has performed consulting services for Ossium and MaaT Pharma.
Chapter 33, Hematopoietic cell transplantation and cellular therapy 4: adoptive cellular therapy Melody Smith reports consulting for CVS Caremark and is an advisor for A28 Therapeutics outside the submitted work. In addition, Dr. Smith has a patent (US 17/229,184) issued, and patents (US 63/303,461 and Stanford Docket S23–380) pending.
Chapter 34, Myeloid disorders: acquired and inherited white blood cell disorders Bhumika J. Patel: nothing to disclose.
Chapter 35, Inherited bone marrow failure syndromes Michael W. Drazer: Consultancy; Argenx, Blueprint Medicines.
Chapter 36, Chronic myeloid leukemia Maximillian Stahl:advisory board membership; Novartis, Kymera, Sierra Oncology, GSK, Rigel, BMS, Sobi and Syndax; consulted; Boston Consulting, Dedham Group, and Kura Oncology; participated in GME activity; Novartis, Curis Oncology, Haymarket Media, Clinical Care Options.
Chapter 37, Myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis Brady Stein: nothing to disclose.
Anand A. Patel: honoraria from AbbVie, Bristol-Myers Squibb, Sobi; research funding (institutional) from Pfizer, Kronos Bio, Sumitomo.
Chapter 38, Beyond the classical Philadelphia chromosome–negative myeloproliferative neoplasms Anand A. Patel: research funding (to institution): Pfizer, Kronos Bio, Sumitomo; honoraria: AbbVie, Bristol-Myers Squibb, Sobi.
Brady Stein: nothing to disclose.
Chapter 39, Acquired bone marrow failure syndromes, including aplastic anemia and pure red cell aplasia Emma M. Groarke: nothing to disclose.
Chapter 40, Myelodysplastic syndromes and premalignant clonal hematopoiesis Lachelle D. Weeks: consultancy: AbbVie, Sobi, and Vertex.
Chapter 41, Acute myeloid leukemia Catherine C. Smith has received research funding from Revolution Medicines, Erasca, and AbbVie and has served on advisory boards for AbbVie, Genentech, and Servier.
Chapter 42, Acute lymphoblastic leukemia Lori Muffly: consultancy: Astellas; research funding: Astellas, Adaptive, BMS, Jasper, Kite, Vor, Wugen; advisory boards: Autolus, Cargo, Kite, Pfizer.
Chapter 43, Hodgkin lymphoma Matthew Mei: Consultancy: Novartis, SeaGen, ADC, Astra- Zeneca, and Synethkine. Speakers’ bureau: SeaGen, Incyte. Research funding: BMS, BeiGene, Incyte, Genentech.
Chapter 44, Indolent non-Hodgkin B-cell lymphoma Sairah Ahmed: Research support to institution for clinical trials from Nektar, Merck, Xencor, Chimagen, and Genmab, Kite/Gilead, Janssen, and Caribou. Consultant for ADC Therapeutics, Kite/Gilead, Genmab, and BMS.
Chapter 45, Aggressive non-Hodgkin and Burkitt lymphomas Allison Rosenthal has received honoraria for educational sessions from Curio Science, RMEI Medical Education LLC, OncLive, and Targeted Oncology.
Chapter 46, T-cell lymphomas Neha Mehta-Shah has received institutional clinical trial funding from AstraZeneca, Bristol-Myers Squibb, Celgene, C4 Therapeutics, Corvus Pharmaceuticals, Daiichi Sankyo, Genentech/Roche, Innate Pharmaceuticals, Secura Bio/ Verastem, Yingli Pharmaceuticals, Morphosys/Novartis, SeaGen, and Dizal Pharmaceuticals. She has received compensation for service as a consultant for AstraZeneca, Secura Bio/Verastem, Daiichi Sankyo, C4 Therapeutics, Genentech, Janssen Karyopharm Therapeutics, Kyowa Hakko Kirin, Ono Pharmaceuticals, Pfizer, and Autolus.
Chapter 47, Chronic lymphocytic leukemia/small lymphocytic lymphoma Jennifer A. Woyach: consulted for AbbVie, AstraZeneca, BeiGene, Genentech, Janssen, Loxo/Lilly, Merck, Newave, and Pharmacyclics and receives research funding from AbbVie, Janssen, Pharmacyclics, and Schrödinger.
Chapter 48, Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma Caitlin L.Costello: honoraria from AstraZeneca, Bristol-Myers Squibb, Janssen, Kite, and Pfizer; Research funding from Bristol-Myers Squibb, Janssen, Pfizer, Poseida and Takeda.
Chapter 49, AL amyloidosis, Waldenström macroglobulinemia, and POEMS syndrome Vaishali Sanchorawala: Advisory board and consultancy for GlaxoSmithKline; research funding (to the institution) from Janssen, Alexion, and Prothena; steering committee for Janssen; advisory board meetings for Prothena, AbbVie, Regeneron, Janssen, and Alexion.
Discussions of off-label drug use are listed below.
The American Society of Hematology requires all authors to disclose any discussion of off-label drug use in their chapters.
Chapter 1, Consultative hematology 1: perioperative management concepts
Fondaparinux for heparin-induced thrombocytopenia; prothrombin complex concentrates for bleeding associated with direct oral anticoagulants.
Chapter 2, Consultative hematology 2: outpatient hematology topics
Granulocyte-stimulating factor outside of severe congenital neutropenia.
Chapter 3, Consultative hematology 3: women’s health issues
Almost all medications are considered off-label in pregnancy
Chapter 4, Pediatric hematology: selected topics
Rituximab for ITP.
Chapter 5, Hematopoietic growth factors
TPO mimetics (romipolostim, eltrombopag, avatrombopag) for chemotherapy-induced thrombocytopenia and myelodysplastic syndrome and to improve posttransplant stem cell recovery or cellular therapy.
Chapter 6, Iron physiology, iron overload, and the porphyrias
Iron chelation therapy.
Chapter 7, Acquired underproduction anemias: anemias in the setting of vitamin and mineral deficiencies
IV iron therapy for pediatric patients with iron deficiency anemia is discussed.
Chapter 8, Anemia of inflammation
Not applicable.
Chapter 9, Anemia in the setting of organ insult, systemic disease, and aging
Not applicable.
Chapter 10, Thalassemia syndromes and other hemoglobinopathies Not applicable.
Chapter 11, Sickle cell disease
Not applicable.
Chapter 12, Hemolytic anemia 1: autoimmune hemolysis
Alemtuzumab, azathioprine, bortezomib, cyclophosphamide, cyclosporine, daratumumab, danazol, erythropoietin, fostimatinib, intravenous immunoglobulin (IVIG), mycophenolate mofetil, and rituximab in the treatment of warm autoimmune hemolytic anemia. Bendamustine, ibrutinib, and rituximab in the treatment of cold agglutinin disease.
Chapter 13, Hemolytic anemia 2: membrane abnormalities and enzymopathies
Not applicable.
Chapter 14, Complement-related disorders
Not applicable.
Chapter 15, Introduction to venous thromboembolism and antithrombotic drugs
4-factor PCC for the reversal of DOAC associated bleeding.
Chapter 16, Atypical-site thrombosis
Direct oral anticoagulants (DOACs) for atypical-site thrombosis, intravenous immunoglobulins (IVIG) for VITT.
Chapter 17, Antiphospholipid syndrome
Not applicable.
Chapter 18, Cancer-associated thrombosis
The use of prophylactic anticoagulant in the ambulatory setting is off-label.
Chapter 19, Inherited thrombophilias
Not applicable.
Chapter 20, von Willebrand disease
Not applicable.
Chapter 21, Hemophilia A and B
Serpin-PC for hemophilia A and B; rituximab for inhibitor eradication in congenital hemophilia A; cyclophosphamide and rituximab for acquired hemophilia A.
Chapter 22, Hereditary hemorrhagic telangiectasia and other bleeding disorders
Tranexamic acid, epsilon-aminocaproic acid, bevacizumab, thalidomide, pomalidomide, pazopanib, and tacrolimus for HHT; tranexamic acid and epsilon-aminocaproic acid for disorders of fibrinolysis.
Chapter 23, Platelet disorders 1: immune thrombocytopenia
Eltrombopag and romiplostim in newly diagnosed ITP; rituximab, mycophenolate mofetil, azathioprine, 6-mercaptopurine, sirolimus, cyclosporine, vinca alkaloids, dapsone, and danazol in treatment of ITP.
Chapter 24, Platelet disorders 2: heparin-induced thrombocytopenia and other anti-PF4 disorders
None of the alternative anticoagulants, except argatroban, is approved for HIT. Bivalirudin is approved for HIT only in patients undergoing cardiac surgery in case of HIT or increased risk for HIT. For VITT and VITT-like disorders, no anticoagulant is approved. IVIG is not approved for HIT, VITT, or VITT-like disorders.
Chapter 25, Platelet disorders 3: thrombotic thrombocytopenic purpura (immune and congenital)
Rituximab as immunosuppressive therapy for thrombotic thrombocytopenic purpura.
Chapter 26, Platelet disorders 4: hereditary thrombocytopenia and qualitative platelet disorders
Antifibrinolytic agents (tranexamic acid and epsilon-aminocaproic acid) for inherited platelet function disorders. Desmopressin for uremic platelet dysfunction and inherited platelet function disorders. Thrombopoietin receptor agonists for hereditary thrombocytopenias. Recombinant factor VIIa for non-Glanzmann thrombasthenia inherited platelet function disorders.
Chapter 27, Laboratory hematology
Not applicable.
Chapter 28, Transfusion medicine
Not applicable.
Chapter 29, Apheresis
Not applicable.
Chapter 30, Hematopoietic cell transplantation and cellular therapy 1: the basics of transplantation
Not applicable.
Chapter 31, Hematopoietic cell transplantation and cellular therapy 2: autologous transplantation
Not applicable.
Chapter 32, Hematopoietic cell transplantation and cellular therapy 3: allogeneic transplantation and graft-versus- host disease
All drugs discussed in this chapter are considered off-label with the exception of abatacept, belumosudil, ibrutinib, and ruxolitinib.
Chapter 33, Hematopoietic cell transplantation and cellular therapy 4: adoptive cellular therapy
Not applicable.
Chapter 34, Myeloid disorders: acquired and inherited white blood cell disorders
Granulocyte colony-stimulating factor (G-CSF) in non-SCN neutropenia; glucocorticoids in autoimmune neutropenias, and histiocytic syndromes; interferon-γ in Erdheim-Chester disease; plerixafor in WHIM syndrome; intravenous immunoglobin in autoimmune neutropenias; interferon-γ in chronic granulomatous disease; colchicine in familial Mediterranean fever; etoposide, methotrexate, cyclosporine, anti-thymocyte globulin, and dexamethasone in hemophagocytic lymphohistiocytosis; topical steroids, nitrogen mustard, psoralen in Langerhans cell histiocytosis; vinblastine, methotrexate, and glucocorticoids in Langerhans cell histiocytosis.
Chapter 35, Inherited bone marrow failure syndromes
Not applicable.
Chapter 36, Chronic myeloid leukemia
Not applicable.
Chapter 37, Myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis
Interferon for MPNs.
Chapter 38, Beyond the classical Philadelphia chromosome–negative myeloproliferative neoplasms
Ruxolitinib for CNL and aCML.
Chapter 39, Acquired bone marrow failure syndromes, including aplastic anemia and pure red cell aplasia
Cyclophosphamide, CSA, azathioprine, sirolimus, ATG, alemtuzumab, and rituximab in PRCA. Romiplostim and alemtuzumab in SAA.
Chapter 40, Myelodysplastic syndromes and premalignant clonal hematopoiesis
Epoetin and darbepoetin alfa; filgrastim and tbo-filgrastim; eltrombopag and romiplostim; ventoclax; ivosidenib; enosidenib.
Chapter 41, Acute myeloid leukemia
Gilteritinib (posttransplant maintenance).
Chapter 42, Acute lymphoblastic leukemia
Blinatumomab, inotuzumab.
Chapter 43, Hodgkin lymphoma
Lenalidomide, temsirolimus, and everolimus for cHL.
Chapter 44, Indolent non-Hodgkin B-cell lymphoma
Not applicable.
Chapter 45, Aggressive non-Hodgkin and Burkitt lymphomas
Venetoclax in R/R MCL, Liso-Cel in CNSL, lenalidomide, pomalidomide, ibrutinib, PD-1 inhibitors in R/R CNSL, brentuximab and nivolumab in PMBCL, brentuximab vedotin, lenalidomide and Bruton’s tyrosine kinase inhibitors in R/R DBLCL, CAR-T in CNSL.
Chapter 46, T-cell lymphomas
Duvelisib, valemetostat, golidicitinib, azacitidine for PTCL, mogamulizumab, valemetostat, lenalidomide in adult T-cell leukemia/lymphoma.
Chapter 47, Chronic lymphocytic leukemia/small lymphocytic lymphoma
Not applicable.
Chapter 48, Plasma cell disorders: monoclonal gammopathy of undetermined significance and multiple myeloma
Venetoclax is not approved for the treatment of multiple myeloma. Proteasome inhibitors and anti-CD38 monoclonal antibodies are not approved for maintenance therapies for multiple myeloma.
Chapter 49, AL amyloidosis, Waldenström macroglobulinemia, and POEMS syndrome
Melphalan, lenalidomide, pomalidomide, bortezomib, cyclophosphamide, dexamethasone, ixazomib, belantamab mafodotin, CAR-T, bispecific antibodies for the treatment of AL amyloidosis.
